Genus Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St · 10/16 05:02

Genus (LON:GNS) Full Year 2024 Results

Key Financial Results

  • Revenue: UK£668.8m (down 3.0% from FY 2023).
  • Net income: UK£7.90m (down 76% from FY 2023).
  • Profit margin: 1.2% (down from 4.8% in FY 2023).
  • EPS: UK£0.12 (down from UK£0.51 in FY 2023).
earnings-and-revenue-growth
LSE:GNS Earnings and Revenue Growth October 16th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genus EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 72%.

Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Valuation

Our analysis of these results suggests Genus may be undervalued based on 6 important criteria we look at. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.